Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver Sells 8,996 Shares

Evolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver sold 8,996 shares of Evolus stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $119,286.96. Following the sale, the chief financial officer now owns 173,583 shares of the company’s stock, valued at approximately $2,301,710.58. The trade was a 4.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website.

Sandra Beaver also recently made the following trade(s):

• On Monday, December 23rd, Sandra Beaver sold 1,586 shares of Evolus stock. The stock was sold at an average price of $10.85, for a total transaction of $17,208.10.

Evolus Stock Down 1.6 %

Shares of NASDAQ:EOLS traded down $0.22 during midday trading on Thursday, hitting $13.25. 663,321 shares of the company’s stock traded hands, compared to its average volume of 593,757. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The company has a market cap of $842.53 million, a PE ratio of -14.56 and a beta of 1.28. The firm’s fifty day moving average price is $13.30 and its two-hundred day moving average price is $13.92. Evolus, Inc. has a twelve month low of $9.25 and a twelve month high of $17.82.

Hedge Funds Weigh In On Evolus

Hedge funds and other institutional investors have recently made changes to their positions in the business. KBC Group NV acquired a new position in Evolus in the 4th quarter worth $49,000. IFP Advisors Inc lifted its holdings in Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock worth $52,000 after buying an additional 4,709 shares in the last quarter. Point72 Asset Management L.P. acquired a new position in Evolus in the 3rd quarter worth $132,000. KLP Kapitalforvaltning AS acquired a new position in Evolus in the 4th quarter worth $106,000. Finally, Rafferty Asset Management LLC acquired a new position in Evolus in the 4th quarter worth $115,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on EOLS shares. Barclays lifted their target price on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Evolus in a research note on Wednesday, March 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Wednesday, March 5th.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.